Abstract
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
Paper Title
Journal
Date
More From: The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders
Paper Title
Journal
Date